24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost.
OBJECTIVE
To investigate the efficacy of dorzolamide 1% (bid or tid) or brinzolamide 1% bid on 24-hour intraocular pressure (IOP) control as well as patients' preference for either drug when added in combination with latanoprost against glaucoma (IOP, >/=18 mmHg).


METHODS
In this randomized crossover study patients were assigned to receive latanoprost plus either dorzolamide or brinzolamide for four weeks. Thereafter, patients underwent 24-hour IOP monitoring while continuing to receive dorzolamide (for two successive days/nights: at first bid then tid) or brinzolamide bid (once overnight). They were then switched over to receive the other test medication for a further four weeks and subsequently reexamined for 24-hour IOP. A questionnaire survey on treatment satisfaction was performed.


RESULTS
In 20 patients dorzolamide bid or tid or brinzolamide bid exerted significant (p < 0.001) reductions of IOP from baseline at all time-points over 24 hours; no difference was detected among the treatment regimens. Significantly (p < 0.05) more patients preferred dorzolamide (n = 9) over brinzolamide (n = 2), whereas nine patients gave a neutral answer.


CONCLUSIONS
Dorzolamide bid or tid and brinzolamide bid when combined with latanoprost therapy elicited significant IOP reduction for 24 hours. It is rational to consider patients' preference of therapeutic regimen especially long-term users such as those with glaucoma.
Nakamura
Yoshimi
Y
Department of Ophthalmology, University of the Ryukyus Faculty of Medicine, Okinawa, Japan.
Ishikawa
Shusaku
S
Nakamura
Yuko
Y
Sakai
Hiroshi
H
Henzan
Ichiko
I
Sawaguchi
Shoichi
S
Clin Ophthalmol. 2008 Dec;2(4):703-8
19668419
J Glaucoma. 1994 Winter;3(4):275-9
19920609
Am J Ophthalmol. 2000 Oct;130(4):429-40
11024415
Am J Ophthalmol. 1998 Sep;126(3):400-8
9744373
J Ocul Pharmacol Ther. 2005 Apr;21(2):170-3
15857284
Arch Ophthalmol. 1996 Aug;114(8):929-32
8694726
Ophthalmology. 1996 Jan;103(1):126-37
8628543
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
12049574
Br J Ophthalmol. 1995 Jan;79(1):12-6
7880782
Curr Med Res Opin. 2005 Apr;21(4):503-8
15899098
Ophthalmic Res. 2007;39(1):24-31
17164574
Arch Ophthalmol. 1991 Aug;109(8):1090-5
1867550
Surv Ophthalmol. 2000 Jan;44 Suppl 2:S141-5
10665516
Ophthalmology. 1996 Jan;103(1):138-47
8628544
J Ocul Pharmacol Ther. 2005 Oct;21(5):395-9
16245966
J Glaucoma. 1998 Apr;7(2):95-104
9559495
Am J Ophthalmol. 2002 Jun;133(6):836-7
12036683
N Engl J Med. 1998 Oct 29;339(18):1298-307
9791148
Ophthalmology. 2000 Feb;107(2):283-7
10690826
Ophthalmology. 2001 Nov;108(11):1943-53
11713061
Ophthalmology. 1996 Nov;103(11):1916-24
8942890
Arch Ophthalmol. 2002 Jul;120(7):915-22
12096962
Ophthalmology. 1995 Dec;102(12):1743-52
9098273
Am J Ophthalmol. 2001 Aug;132(2):235-43
11476685